NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NUZ

NUZ - NEURIZON THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.063

28 May
2026

-0.003

OPEN

$0.07

-4.55%

HIGH

$0.07

213,390

LOW

$0.06

TARGET
$0.20 217.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NUZ: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 3.4 N/A xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-3.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-14.3 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-254.33 %
Return on Invested Capital xxxxxxxxxxxxxxx-254.33 %
Return on Assets xxxxxxxxxxxxxxx-214.34 %
Return on Equity xxxxxxxxxxxxxxx-254.33 %
Return on Total Capital xxxxxxxxxxxxxxx-283.18 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx4 M
Price To Book Value xxxxxxxxxxxxxxx27.94

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx18 M
Research & Development xxxxxxxxxxxxxxx12 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

28/05/2026

1

Speculative Buy

$0.20

217.46%

Morgans views Neurizon Therapeutics' expanded Healey amyotrophic lateral sclerosis (ALS)/MND trial cohort as a net positive, improving the statistical robustness and commercial relevance of the dataset while potentially accelerating timelines.

The broker highlights unusually strong enrolment momentum, with recruitment tracking materially ahead of schedule despite the larger cohort size, and topline results now expected in 3Q 2027.

Importantly, the Healey Center will fund most incremental trial costs, leaving Neurizon's funding requirements unchanged.

While Morgans notes clinical risk remains high given ALS's poor history of late-stage trial success, the broker retains a Speculative Buy rating and 20c target, down from 28c.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

NUZ STOCK CHART

FNArena News on NUZ

1
Australian Broker Call *Extra* Edition – Oct 08, 2025

Oct 08 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 25, 2025

Aug 25 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 19, 2025

Aug 19 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 14, 2025

Aug 14 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
2
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
3
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
4
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
5
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
6
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
7
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
8
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
9
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
10
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals